# Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

> **NCT07363252** · — · RECRUITING · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 100 (estimated)

## Conditions studied

- EGFR-mutated NSCLC

## Interventions

- **DRUG:** Osimertinib

## Key facts

- **NCT ID:** NCT07363252
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07363252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07363252, "Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07363252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*